In 513 virologically suppressed adults with HIV-1, switching to doravirine/islatravir was non-inferior to continuing bictegravir/emtricitabine/tenofovir alafenamide at week 48 (viral load ≥50 copies/mL 1.5% vs 0.6%).
RCTn = 514
Colson et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial